American Cancer Society - Promising--yet preliminary--results from an early clinical trial show
that the experimental drug abiraterone can significantly reduce the
size of prostate
cancer tumors in men who haven't responded to other
therapies.
that the experimental drug abiraterone can significantly reduce the
size of prostate
cancer tumors in men who haven't responded to other
therapies.